InvestorWire NewsRoom


Articles Category: Biotechnology
Thursday Nov 16, 2023 - 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program

Clene recently released its financial results for the third quarter ended September 30, 2023, and provided recent operating highlights for its ALS clinical program The ALS clinical program includes two independent studies evaluating the safety and efficacy of the company’s lead investigational product CNM-Au8(R) The 24-month long-term data cut from the open-label extension of the RESCUE-ALS study showed a significant median survival benefit of 19.3…

Continue Reading

Tuesday Nov 14, 2023 - 9:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is Hoping to Boost Patient Independence with Potential ASD Treatment Amid Growing Prevalence Rates

PaxMedica is developing PAX-101, which utilizes the company’s proprietary source of suramin sodium, for the treatment of ASD (Autism Spectrum Disorder) There is no FDA-approved treatment for the core symptoms of autism, even though the rates of autism spectrum disorder have jumped significantly from 2000 to 2020 ASD is characterized by deficits in social communication, restricted and repetitive patterns of behavior, and significant impairment in…

Continue Reading

Thursday Oct 19, 2023 - 10:30 am

SOHM, Inc. (SHMN) Completes Acquisition of ABBIE Gene-editing Tech, Begins Preparations to Commercialize Solutions for Heart Disease

Generic drug manufacturer and distributor SOHM has completed the LOI process to acquire stem cell gene-editing technology ABBIE from CGA Intellectual Holdings Inc. The company expects the technology to provide it with commercialization revenues as it builds a solution for gene-enhanced stem cells that can be used to treat a number of diseased organs, beginning with heart ailments The edited-gene cells are expected to be…

Continue Reading

Thursday Oct 12, 2023 - 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) CEO Presents ASD Pipeline and Corporate Presentation at H.C. Wainwright 25th Annual Global Investment Conference

Howard Weisman presented PaxMedica’s goals and plans to investors at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 The presentation defined the company’s intention to generate significant funding for its ASD program by first gaining approval for suramin sodium in the treatment of a rare and deadly infection using the same drug The global ASD treatment market was valued at $2.02…

Continue Reading

Wednesday Oct 04, 2023 - 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development

Scinai Immunotherapeutics recently announced the closing of a registered direct offering, raising $1.33 million in gross proceeds The company intends to use the net proceed from the offering for, among others, research and development On its R&D agenda is the development and commercialization of novel innovative NanoAbs targeting a wide range of diseases with known and validated antibody drug targets This strategic approach is expected…

Continue Reading

Monday Oct 02, 2023 - 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification

Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs Amir Reichman took over as CEO in March 2021 and together with the Board of…

Continue Reading

Friday Sep 29, 2023 - 11:15 am

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video:  Progress Report on ASD and Hope for the Future

Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials In 2024, we're poised to submit a New Drug Application…

Continue Reading

Thursday Sep 28, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a…

Continue Reading

Thursday Sep 28, 2023 - 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on…

Continue Reading

Wednesday Sep 27, 2023 - 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty Longeveron (NASDAQ: LGVN),…

Continue Reading

Monday Sep 25, 2023 - 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50…

Continue Reading

Wednesday Sep 20, 2023 - 11:15 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers GEDI Cube…

Continue Reading

Wednesday Sep 20, 2023 - 9:00 am

Generic Drug Manufacturer SOHM, Inc. (SHMN) Building Regenerative Medicine Platform with LOI for Gene Editing Technology

U.S.-based generic drug developer SOHM is working to build its product pipeline through registration for distribution in several states and the planned establishment of its own product manufacturing plant in Southern California SOHM is also focused on developing a regenerative medicine portfolio, having issued an LOI recently in its bid to acquire the gene editing technology ABBIE from CGA Intellectual Holdings Inc. ABBIE is a…

Continue Reading

Wednesday Sep 13, 2023 - 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024 The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD PaxMedica submitted PAX-101 Clinical Trial Request to the South African Health Products…

Continue Reading

Tuesday Sep 12, 2023 - 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating…

Continue Reading

Monday Sep 11, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to…

Continue Reading

Friday Sep 08, 2023 - 10:30 am

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

In July 2023, LSDI launched Twilight, a new sleep aid product The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life Also in May 2023,…

Continue Reading

Friday Sep 08, 2023 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year Based on the…

Continue Reading

Thursday Sep 07, 2023 - 9:30 am

The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction

Lucy Scientific Beats MindMed and Seelos Therapeutics to the Punch Lucy Scientific Discovery (NASDAQ: LSDI) (“Lucy” or the “Company), a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses, just announced the acquisition of the Intellectual Property of High Times, its Licensing Agreements and Royalty Streams in all-stock transaction. This was a brilliant strategic business move. With first movers in the “Mind…

Continue Reading

Tuesday Sep 05, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced…

Continue Reading

Wednesday Aug 30, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”) The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”) The orphan drug designation…

Continue Reading

Friday Aug 25, 2023 - 9:45 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Aims to Unlock Potential Treatments and Cures for Serious Infectious Diseases and Cancer

Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results As an…

Continue Reading

Wednesday Aug 23, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan…

Continue Reading

Wednesday Aug 23, 2023 - 9:00 am

Renovaro BioSciences Inc. (NASDAQ: RENB), Immunotherapy Biotech Company, Announces Intention to Unite With AI Tech Developer GEDi Cube, Seen as Major Multiplier Effect in the Fight Against Cancer

Combination of advanced AI machine learning technology and proven immunotherapy technology seen as “future of medicine” Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically Potential applications against variety of cancers The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing…

Continue Reading

Friday Aug 18, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment

Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has…

Continue Reading

Monday Aug 14, 2023 - 11:15 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics

Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030 The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030 The…

Continue Reading

Monday Aug 14, 2023 - 9:00 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment…

Continue Reading

Friday Jul 28, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda The company has received patent protection for…

Continue Reading

Wednesday Jul 26, 2023 - 9:45 am

M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market DICE Therapeutics is…

Continue Reading

Friday Jul 21, 2023 - 9:00 am

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it…

Continue Reading

Wednesday Jul 19, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast

Reichman discusses BiondVax’s 2023 achievements, including the development of innovative NanoAbs in collaboration with the Max Planck Institute targeting interleukin-17 (IL-17) targeting diseases such as psoriasis Annual sales for current anti-interleukin-17 monoclonal antibodies now total about $7.5 billion annually – and BiondVax is positioned to penetrate this market with promising results Investor Brand Network (“IBN”) recently announced the release of its latest episode of The…

Continue Reading

Monday Jul 10, 2023 - 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety…

Continue Reading

Monday Jul 03, 2023 - 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services

BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining…

Continue Reading

Friday Jun 23, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode

Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements In May, the company received Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial of its lead candidate, REQORSA(R) Immunogene Therapy The Phase 1 dose escalation portion of the study showed that REQORSA(R) was…

Continue Reading

Thursday Jun 22, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Gains Exclusive Development and Commercialization License from Max Planck for biobetter Anti-IL-17 Antibody

BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis BiondVax…

Continue Reading

Tuesday Jun 20, 2023 - 11:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Focus with Development of New NanoAb Therapeutics

Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such…

Continue Reading

Tuesday Jun 20, 2023 - 10:15 am

Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors

U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its…

Continue Reading

Friday Jun 02, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Displays CDMO Expertise at Prestigious Biomed Israel Conference

Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which…

Continue Reading

Friday Jun 02, 2023 - 9:15 am

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

Gene Therapy's Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex's innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer. The…

Continue Reading

Tuesday May 30, 2023 - 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update

Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).